Bondarenko N.A., Ostrovskaya R.U., Gudasheva T.A., Durnev A.D.

Introduction. Taken into account the literature data on the leading role of perceptual deficit in the pathogenesis of schizophrenia and the lack of experimental models of this impairment we proposed the novel test of instinctive aversion (TIA). The work was performed in order to evaluate the translational validity of this test in the study of the effect of different neuroleptics: representing the group of typical, atypical neuroleptics, as well as novel,neurotensin dipeptide analogDilept in TIA test and to compare with their activity in tests commonly used for screening of neuroleptics : apomorphine (APO) induced climbing and l-DOPA induced disturbance in the test of extrapolative escape (TEE). Methods. Experiments were performed on outbred rats (TIA and TEE) and CC57/W mice (climbing test) by using the equipment of «Open Science» Company. APO in doses of 2 mg/kg and l-DOPA (Madopar) in doses of 125 mg/kg were administered subcutaneously or intraperitoneally correspondingly. Results. All neuroleptics under study independently on their chemical structure demonstrated the ability to ameliorate the effect of APO in TIA. Their activity was confirmed in standard tests. TIA was shown to exist in adult (PD 90) or youngsters (PD 50) only, but not in immature rats. Peculiarities of neurochemical mechanisms underlying the effect of APO and L-DOPA are proposed to be a reason of certain difference in the level of threshold doses for all three tests. Conclusion. The suggested model meets criteria of constructive, obvious and predictive validity and is suitable for the screening of neuroleptics.
schizophrenia, modeling of cognitive deficits, antipsychotics, Dilept, neurotensin dipeptide analogue

Список литературы: 
  1. Sawa A., Snyder S.H. Schizophrenia: diverse approaches to a complex disease. Science. 2002; 296: 692–5.
  2. Barch D.M., Ceaser A. Cognition in Schizophrenia: Core Psychological and Neural Mechanisms. Trends Cogn. Sci. 2012; 16 (1): 1–12.
  3. Stip E. Cognition, schizophrenia and the effect of antipsychotics. Encephale. 2006; 32 (3 Pt 1): 341–50.
  4. Pal`cev M.A., Belushkina N.N. Translyacionnaya medicina – novyy e`tap razvitiya molekulyarnoy mediciny. Molekulyarnaya medicina. 2012; 4: 3–6. [Paltsev M.A., Belushkina N.N. Translational medicine – a new stage of molecular medicine development. Molekuljarnaya medicina (Russia). 2012; 4: 3–6 (in Russian)]
  5. Geyer M.A., Krebs-Thomson K., Braff D.L. Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 2001; 156: 117–54.
  6. Swerdlow N.R., Weber M., Qu Y., Light G.A., Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008; 199 (3): 331–88.
  7. Geyer M.A. Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia? Dialogues Clin Neurosci. 2006; 8 (1): 9–16.
  8. Badgaiyan R.D. Nonconscious processing and a novel target for schizophrenia research. Open J. Psychiatr. 2012; 2 (4A): 10.4236/ojpsych.2012.224047.
  9. Javitt D.C. When Doors of Perception Close: Bottom-up Models of Disrupted Cognition in Schizophrenia. Annu. Rev. Clin. Psychol. 2009; 5: 249–75.
  10. Ershov B.B. Narusheniya perceptivnoy organizacii psihicheskoy deyatel`nosti bol`nyh shizofreniey. Vestnik Yuzhno-Ural`skogo gosudarstvennogo universiteta. Seriya: Psihologiya. 2011; 5 (222): 107–14. [Ershov B.B. Disturbances of psychic perceptive organization in schizophrenics, Vestnik Juzhno-Uralskogo gosudarstvennogo Universiteta Seria Psihologia. 2011; 5 (222): 107–14 (in Russian)]
  11. Siegel S.J., Talpos J.C., Geyer M.A. Animal models and measures of perceptual processing in Schizophrenia. Neurosci. Biobehav. Rev. 2013; 37 (9 0 0): 10.1016/j.neubiorev.2013.06.016.
  12. Chen Y., Ekstrom T.. Visual and associated affective processing of face information in schizophrenia: A selective review. Curr. Psychiatry Rev. 2015; 11 (4): 266–72.
  13. Vladimirova E`.D. Psihologiya zhivotnyh: Uchebnoe posobie. Samara: Samarskiy universitet, 2010; 134. [Vladimirova E.D. Psihologija zhivotnih : utchebnoe posobie. Samara. Samarskij universitet, 2010; 134 (in Russian)]
  14. Bondarenko N.A. Reakcii-dvoyniki v povedenii krys. Vserossiyskaya konferenciya po povedeniyu zhivotnyh: Sb. tezisov. M.: Tovarishhestvo nauchnyh izdaniy KMK, 2012; 19. [Bondarenko N.A. «Twins reactions» in a rat’s behavior. All-Russian conference on animal behavior: Coll. theses. M.: Tovarichestvo nauchnih izdanij KMK, 2012; 19 (in Russian)]
  15. Bondarenko Nina A. 2014. «GDE?» i «KAK?» v celenapravlennom poiskovom povedenii krys. Shestaya mezhdunarodnaya konferenciya po kognitivnoy nauke: Tezisy dokladov. Kaliningrad, 23–27 iyunya 2014 [Bondarenko N.A. «Where» and «how» in the spatial exploratory behavior of rats. The sixth international conference on cognitive science. Kaliningrad, June 23–27, 2014 (in Russian)]
  16. Puech A.J., Simon P., Boissier J.R. Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur. J. Pharmacol. 1978; 50 (4): 291–300.
  17. Raevskiy K.S., Narkevich V.B. Metodicheskie ukazaniya po izucheniyu neyrolepticheskoy aktivnosti farmakologicheskih veshhestv. Rukovodstvo po e`ksperimental`nomu (doklinicheskomu) izucheniyu novyh veshhestv. M.: Remedium, 2000; 114–20.
  18. Ostrovskaya R.U., Krupina N.A., Gudasheva T.A., Voronina T.A., Seredenin S.B. Oslablenie deficita predstimul`nogo tormozheniya dipeptidnym analogom neyrotenzina, dileptom – prognosticheskiy priznak ego antipsihoticheskogo deystviya. E`ksperimental`naya i klinicheskaya farmakologiya. 2009; 72 (5): 3–7. [Ostrovskaya R.U.,Krupina N.A., Gudasheva T.A., Voronina T.A., Seredenin S.B. Attenuation of prepulse inhibition deficit by dipeptide analogue of neurotensin, Dilept as a prognostic sign of its antipsychotic activity. Eksperimentaljnaja i klinicheskaja farmakologia. 2009; 72 (5): 3–7 (in Russian)]
  19. Young J.W., Geyer M.A. Developing treatments for cognitive deficits in schizophrenia: The challenge of translation. J. Psychopharmacol. 2015; 29 (2): 178–96.
  20. Gudasheva T.A., Voronina T.A., Ostrovskaya R.U., Zaitseva N.I., Bondarenko N.A., Briling V.K., Asmakova L.S., Rozantsev G.G., Seredenin S.B. Design of N-Acylprolyltyrosine “Tripeptoid” Analogues of Neurotensin as Potential Atypical Antipsychotic Agents. J. Med. Chem. 1998; 41 (3): 284–90.
  21. Seredenin S.B., Voronina T.A., Gudasheva T.A., Ostrovskaya R.U., Rozancev G.G., Bondarenko N.A. Zameshhennye proliltiroziny, obladayushhie psihotropnoy aktivnost`yu: Patent №2091390. Rossiya. Zayavl. 28.02.95. Opubl. 27.09.97. Byul. №27. [Seredenin S.B., Voronina T.A., Gudasheva T.A., Ostrovskaya R.U., Rozantsev G.G., Bondarenko N.A. Substituted prolyltyrosines, possessing psychotropic activity. Appl. 28.02.95. Publ. 27.09.97. Bul. №27 (in Russian)]
  22. Protais P., Costentin J., Schwartz J.C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology (Berl). 1976; 50: 1–6.
  23. Bondarenko H.A. Poisk neyroleptikov na osnove analiza dofaminzavisimogo narusheniya kognitivnyh funkciy: dis ... kand. biol. nauk. M., 1992. [Bondarenko N.A. The search of neuroleptics on the basis of dopamine-dependent cognitive deficit model. Moscow, PhD thesis, 1992 (in Russian)]
  24. Megens A.A., Hendrickx H.M.R., Lavreysen H, Langlois X Differential interaction of neuroleptics with apomorphine-induced behavior in rats as a function of changing levels of dopamine receptor stimulation. J. Pharmacol. Exp. Ther. 2013; 347 (3): 681–96 doi: 10.1124/jpet.113.207506.
  25. Bondarenko N.A. 2013. Izuchenie vozmozhnosti formirovaniya celenapravlennogo povedeniya u krys s «odnoy proby» v teste «E`kstrapolyacionnoe izbavlenie». E`volyucionnaya i sravnitel`naya psihologiya v Rossii: tradicii i perspektivy. Pod red. A.N. Haritonova. M.: Institut psihologii RAN, 2013; 122–30. [Bondarenko N.A., 2013. The «one sample» goal-directed behavioral formation in the extrapolatory escape test. Evolutionary and comparative psychology in Russia: traditions and perspectives. Ed. AN Kharitonov. M.: Institute of Psychology, Russian Academy of Sciences, 2013; 122–30 (in Russian)]
  26. Bondarenko N.A. Mysh`, zagnannaya v ugol. Povedenie i povedencheskaya e`kologiya mlekopitayushhih. Materialy 3-y nauchnoy konferencii 14–16 aprelya 2014 g., g. Chernogolovka. M.: Tov-vo nauchnyh izdaniy KMK. [Bondarenko N.A. Mouse cornered In: behavior and behavioral ecology of mammals. Proceedings of the 3rd scientific conference on 14–16 April 2014., Chernogolovka. M.: Tovarichestvo nauchnih izdanij KMK (in Russian)]
  27. Newman-Tancredi A., Cussac D., Quentric Y. et al. Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes The J. of Pharmacol. and Exp. Therapeutics. 2002; 303 (2): 815–22.
  28. Feng M., Gao J., Sui N., Li M. Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test. Psychopharmacology (Berl). 2015; 232 (7): 1219–30.
  29. Schmid C.L., Streicher J.M., Meltzer H.Y, Bohn L.M. Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt. Neuropsychopharmacology. 2014; 39 (8): 1902–13.
  30. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013; 28 (8): 1088–96.
  31. Fresnoza S., Stiksrud E., Klinker F., Liebetanz D., Paulus W., Kuo M.F., Nitsche M.A. Dosage-Dependent Effect of Dopamine D2 Receptor Activation on Motor Cortex Plasticity in Humans. J. Neurosci. 2014; 34 (32): 10701–9.
  32. Fresnoza S., Paulus W., Nitsche M.A., Kuo M.F. Nonlinear dose-dependent impact of D1 receptor activation on motor cortex plasticity in humans. J. Neurosci. 2014; 34 (7): 2744–53.
  33. Yohn S.E., Santerre J.L., Nunes E.J., Kozak R., Podurgiel S.J., Correa M., Salamone J.D. The role of dopamine D1 receptor transmission in effort-related choice behavior: Effects of D1 agonists. Pharmacol. Biochem. Behav. 2015; 135: 217–26.
  34. Tochilov V.A. Kushnir O.N. Klozapin preparat vybora dlya lecheniya bol`nyh s ostrymi psihozami. Social`naya i klinicheskaya psihiatriya. 2011; 21 (2): 37–42. [Tochilov V.A., Kushnir O.N. Klozapine as a first choice drug for the treatment of acute psychoses . Sozialinaja i klinicheskaja psichjatrija. 2011; 21 (2): 37–42 (in Russian)]
  35. Tyuvina N.A., Prohorova S.V., Maksimova T.N E`ffektivnost` i osobennosti deystviya sul`pirida pri vyalotekushhey shizofrenii. Psihicheskie rasstroystva v obshhey medicine. 2011; 1: 51–5. [Tiuvina N.A., Prohorova S.B., Maksimova T.N. Effectiveness and peculiarities of sulpiride in continuous sluggish schizophrenia. Psihitcheskie rasstrojstva v obchej medizine 2011; 1: 51–5 (in Russian)]
  36. Laursen L.A, Gerlach J. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. Acta Psychiatr. Scand. 1986; 73 (1): 17–21.
  37. Neznamov G.G., Bogdanova I.O., Syunyakov S.A., Syunyakov T.S., Shabanova A.A., Kovalenok T.V., Ivashkina N.Yu. Rezul`taty pilotnogo klinicheskogo issledovaniya terapevticheskogo deystviya novogo antipsihotika peptidnoy prirodv dilepta u bol`nyh s nevrozopodobnymi narusheniyami pri shizotipicheskom rasstroystve. E`ksperimental`naya i klinicheskaya farmakologiya. 2015; 78: 46. [Neznamov G.G., Bogdanova I.O., Sjunjakov S.A., Sjunjakov T.S., Shabanova A.A., Kovalenok T.V., Ivashkina N.Ju. Pilot clinical study of therapeutic activity of the novel dipeptidal antipsychotic, Dilept in patients with neurose- like schizotypic pathology. Eksperimentaljnaja i klinicheskaja farmakologia. 2015; 78: 46 (in Russian)]
  38. Jones C.A., Watson D.J.G., Fone R.C.F. Animal models of schizophrenia. Br. J. Pharmacol. 2011; 164 (4): 1162–94.
  39. Tirelli E., Laviola G., Adriani W. Ontogenesis of behavioral sensitization and conditioned place preference induced by psychostimulants in laboratory rodents. Neurosci Biobehav Rev. 2003; 27 (1–2): 163–78.
  40. Ostrovskaya R.U., Retyunskaya M.V., Guzevatyh L.S., Gudasheva T.A., Voronina T.A., Seredenin S.B. Tripeptoidnyy analog neyrotenzina dilept sochetaet neyrolepticheskuyu aktivnost` s polozhitel`nym mnemotropnym deystviem. E`ksperimental`naya i klinicheskaya farmakologiya. 2005; 68 (1): 3–6. [Ostrovskaya R.U., Retjunskaya M.V., Guzevatich L.S., Gudasheva T.A., Voronina T.A., Seredenin S.B. Tripeptoid analogue of neurotensin combines the neuroleptic activity with positive mnemotropic action. Eksperimentaljnaja i klinicheskaja farmakologia. 2005, 68 (1): 3–6.